PMID- 25089507
OWN - NLM
STAT- MEDLINE
DCOM- 20150807
LR  - 20140924
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 474
IP  - 1-2
DP  - 2014 Oct 20
TI  - Polyester-idarubicin nanoparticles and a polymer-photosensitizer complex as 
      potential drug formulations for cell-mediated drug delivery.
PG  - 70-9
LID - S0378-5173(14)00547-X [pii]
LID - 10.1016/j.ijpharm.2014.07.048 [doi]
AB  - Cell-mediated transport of therapeutics has emerged as promising alternative to 
      classical drug delivery approaches. To preserve viability and functions of 
      carrier cells, encapsulation of active drugs in protective nanoparticles or the 
      use of inducible therapeutics has been proposed. Here, we compared the effects of 
      novel polymeric formulations of an active and a stimulus-sensitive anti-cancer 
      drug on human T lymphocytes to identify suitable drug preparations for 
      cell-mediated drug delivery. For the first approach, the chemotherapeutic agent 
      idarubicin (IDA) was encapsulated in poly(lactic-co-glycolic-acid) (PLGA) and 
      newly developed maleate-polyester (MPE) nanoparticles. PLGA- and MPE-encapsulated 
      IDA was efficiently internalized by ex vivo activated human T lymphocytes; 
      however, both encapsulations could not prevent premature T cell death resulting 
      from IDA-uptake. In contrast, loading with a poly(styrene sulfonate) 
      (PSS)-complex of the light-sensitive pharmaceutical 
      5,10,15,20-tetrakis(meso-hydroxyphenyl)porphyrin (mTHPP) did not affect T cell 
      viability if upon loading the cells were kept in the dark. The photosensitizer 
      was transferred from loaded T lymphocytes to co-cultivated carcinoma cells, and 
      induced cancer cell death if co-cultures were exposed to light. Inducible drugs, 
      such as photosensitizers, thus, may help to overcome the limitations of 
      encapsulated active drugs and open up new perspectives for the use of cells as 
      drug transporters in cancer therapy.
CI  - Copyright (c) 2014 Elsevier B.V. All rights reserved.
FAU - Blaudszun, Andre-R
AU  - Blaudszun AR
AD  - Cellular Immunotherapy Team and Environment and Bio Group, Korea Institute of 
      Science and Technology (KIST) Europe, Saarbrucken 66123, Germany.
FAU - Lian, Qiong
AU  - Lian Q
AD  - Biopharmaceutics and Pharmaceutical Technology, Saarland University, Saarbrucken 
      66123, Germany.
FAU - Schnabel, Melanie
AU  - Schnabel M
AD  - Organic Macromolecular Chemistry, Saarland University, Saarbrucken 66123, 
      Germany.
FAU - Loretz, Brigitta
AU  - Loretz B
AD  - Biopharmaceutics and Pharmaceutical Technology, Saarland University, Saarbrucken 
      66123, Germany; Department of Drug Delivery, Helmholtz Institute for 
      Pharmaceutical Research Saarland (HIPS), Saarbrucken 66123, Germany.
FAU - Steinfeld, Ute
AU  - Steinfeld U
AD  - Cellular Immunotherapy Team and Environment and Bio Group, Korea Institute of 
      Science and Technology (KIST) Europe, Saarbrucken 66123, Germany.
FAU - Lee, Hyeck-H
AU  - Lee HH
AD  - Cellular Immunotherapy Team and Environment and Bio Group, Korea Institute of 
      Science and Technology (KIST) Europe, Saarbrucken 66123, Germany.
FAU - Wenz, Gerhard
AU  - Wenz G
AD  - Organic Macromolecular Chemistry, Saarland University, Saarbrucken 66123, 
      Germany.
FAU - Lehr, Claus-M
AU  - Lehr CM
AD  - Biopharmaceutics and Pharmaceutical Technology, Saarland University, Saarbrucken 
      66123, Germany; Department of Drug Delivery, Helmholtz Institute for 
      Pharmaceutical Research Saarland (HIPS), Saarbrucken 66123, Germany.
FAU - Schneider, Marc
AU  - Schneider M
AD  - Pharmaceutical Nanotechnology, Saarland University, Saarbrucken 66123, Germany; 
      Pharmaceutics and Biopharmacy, Philipps University Marburg, Marburg 35032, 
      Germany.
FAU - Philippi, Anja
AU  - Philippi A
AD  - Cellular Immunotherapy Team and Environment and Bio Group, Korea Institute of 
      Science and Technology (KIST) Europe, Saarbrucken 66123, Germany. Electronic 
      address: a.philippi@kist-europe.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140730
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Polymers)
RN  - ZRP63D75JW (Idarubicin)
SB  - IM
MH  - Cells, Cultured
MH  - Chemistry, Pharmaceutical
MH  - *Drug Delivery Systems
MH  - Humans
MH  - Idarubicin/*chemistry
MH  - Molecular Structure
MH  - Nanoparticles/*chemistry
MH  - Particle Size
MH  - Photosensitizing Agents/*chemistry
MH  - Polymers/chemical synthesis/*chemistry
MH  - Surface Properties
MH  - T-Lymphocytes/chemistry
OTO - NOTNLM
OT  - Gold shell nanoparticle
OT  - Photosensitizer
OT  - Polymeric nanoparticle
OT  - T lymphocyte
OT  - Targeted drug delivery
EDAT- 2014/08/05 06:00
MHDA- 2015/08/08 06:00
CRDT- 2014/08/05 06:00
PHST- 2014/05/13 00:00 [received]
PHST- 2014/07/22 00:00 [revised]
PHST- 2014/07/26 00:00 [accepted]
PHST- 2014/08/05 06:00 [entrez]
PHST- 2014/08/05 06:00 [pubmed]
PHST- 2015/08/08 06:00 [medline]
AID - S0378-5173(14)00547-X [pii]
AID - 10.1016/j.ijpharm.2014.07.048 [doi]
PST - ppublish
SO  - Int J Pharm. 2014 Oct 20;474(1-2):70-9. doi: 10.1016/j.ijpharm.2014.07.048. Epub 
      2014 Jul 30.